| Name | Title | Contact Details |
|---|
Cutera was established in the San Francisco Bay Area (Brisbane) in 1998 by veteran laser and optical engineers. As the pioneer of Nd:YAG technology, CUTERA® is the trusted authority in Face + Body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. At Cutera, we`re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. CUTERA`s premium portfolio of products include: xeo®, truSculpt® and excel V™. In 2014, CUTERA introduced two new exciting additions to their family of premium products: excel HR™ for high-speed, comfortable, hair removal and enlighten™, the industry`s first Picosecond + Nanosecond + 2 Wavelength High-Powered laser system. Today, our worldwide presence is represented in 40 countries, with direct operations in North America, France, Australia, Belgium, the Netherlands and Luxembourg.
FDI Medical Div. UniMed is a Natick, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AMR Medical /AR Technologies Company (ARTCO) is a Fresno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
D and D Medical Inc is a Goodlettsville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CryoLife`s mission is to partner with clinicians to restore health by delivering innovative technologies. CryoLife is one of the world`s leading medical device companies, providing preserved human tissues for cardiac and vascular surgeries, mechanical heart valves for aortic or mitral valve replacement, surgical adhesives and sealants, vascular grafts, and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery. CryoLife is a pioneer and leader in processing, preserving and distributing human tissues, for use in cardiac and vascular surgeries. Founded in 1984, CryoLife was the first biomedical company to specialize in low temperature preservation of human heart valves used for complex cardiac reconstruction, primarily in children born with heart defects. Since the company`s inception, it is estimated that Cryolife has received tissues from over 145,000 donors and CryoLife products and tissues have been implanted in over 1 million patients worldwide. CryoLife is headquartered in Kennesaw, Georgia, with offices in Austin, Texas, Guildford, Surrey, UK, and Hechingen, Germany, as well as sales and marketing centers in Singapore, and representation in over 85 countries worldwide. The firm`s 1000+ employees hail from 11 countries and speak 17 languages. CryoLife`s staff includes numerous full-time physicians and Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry. CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.